Aclaris Therapeutics (ACRS) News Today $1.47 -0.06 (-3.92%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.42 -0.04 (-3.06%) As of 06/13/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $9.71 Average Price Target from AnalystsJune 15 at 2:09 AM | americanbankingnews.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Recommendation of "Buy" by BrokeragesShares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have been given an average rating of "Buy" by the nine brokerages that are currently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendJune 12 at 3:56 AM | marketbeat.comBank of America Corp DE Buys 196,708 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Bank of America Corp DE raised its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 2,246.3% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 205,465 shares of the biotechnology company's stock after purchasing an additional 196,70June 11, 2025 | marketbeat.comAclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic DermatitisJune 2, 2025 | finance.yahoo.comWhat is Wedbush's Estimate for ACRS Q2 Earnings?Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities research analysts at Wedbush issued their Q2 2025 earnings per share (EPS) estimates for Aclaris Therapeutics in a research note issued to investors on Wednesday, May 28th. Wedbush analyst M. Fan anticipates that the biotechnologyMay 31, 2025 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Stake Lowered by Two Sigma Advisers LPTwo Sigma Advisers LP reduced its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 24.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 977,400 shares of the biotMay 30, 2025 | marketbeat.comMillennium Management LLC Decreases Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Millennium Management LLC lessened its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 34.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,959,047 shares of the biotechnology company's stock after selling 1,046,551 shMay 30, 2025 | marketbeat.comAclaris Therapeutics to Present at Two Major Healthcare Conferences in June 2025May 29, 2025 | msn.comWedbush Initiates Coverage of Aclaris Therapeutics (ACRS) with Outperform RecommendationMay 29, 2025 | msn.comAclaris Therapeutics (NASDAQ:ACRS) Now Covered by WedbushWedbush started coverage on Aclaris Therapeutics in a research report on Wednesday. They issued an "outperform" rating and a $8.00 target price for the company.May 29, 2025 | marketbeat.comAclaris Therapeutics to Participate in Two June Healthcare ConferencesMay 28, 2025 | globenewswire.comStonepine Capital Management LLC Has $1.65 Million Stock Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Stonepine Capital Management LLC cut its position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 73.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 663,405 shares of the biotechnology compaMay 20, 2025 | marketbeat.comJanus Henderson Group PLC Takes $6.99 Million Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Janus Henderson Group PLC bought a new position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 2,799,759 shares of the biotechnology company's stockMay 20, 2025 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by BrokeragesAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has earned a consensus rating of "Buy" from the eight ratings firms that are currently covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buMay 20, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Sells 339,467 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Jacobs Levy Equity Management Inc. reduced its position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 37.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 576,042 shares of the biotecMay 19, 2025 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Bought by Cubist Systematic Strategies LLCCubist Systematic Strategies LLC lifted its holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 3,573.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 256,092 shares of the biotechnMay 18, 2025 | marketbeat.comAclaris Therapeutics to Host Virtual Fireside Chat with CEO Neal Walker on May 16, 2025May 13, 2025 | msn.comAclaris Therapeutics Reports Q1 2025 Results and Pipeline UpdatesMay 11, 2025 | msn.comAclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” SeriesMay 9, 2025 | globenewswire.comAclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | globenewswire.com217,265 Shares in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Purchased by 683 Capital Management LLC683 Capital Management LLC acquired a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 217,265 shares of the biotechnology company's stock, vaMay 4, 2025 | marketbeat.comRA Capital Management L.P. Purchases New Shares in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)RA Capital Management L.P. acquired a new position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 4,666,667 shares of the biotechnology company's stock, valuMay 3, 2025 | marketbeat.com888,888 Shares in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Acquired by Monashee Investment Management LLCMonashee Investment Management LLC purchased a new stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 888,888 shares of the biotechnology company's stock, valued at appMay 2, 2025 | marketbeat.comSamsara BioCapital LLC Buys 1,688,889 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Samsara BioCapital LLC increased its position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 242.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,385,060 shares of the biotechMay 2, 2025 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 34.8% in AprilAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) saw a large drop in short interest in April. As of April 15th, there was short interest totalling 4,070,000 shares, a drop of 34.8% from the March 31st total of 6,240,000 shares. Based on an average trading volume of 902,300 shares, the short-interest ratio is presently 4.5 days. Currently, 6.1% of the company's stock are sold short.May 2, 2025 | marketbeat.comAclaris Therapeutics (ACRS) Expected to Announce Earnings on TuesdayAclaris Therapeutics (NASDAQ:ACRS) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-aclaris-therapeutics-inc-stock/)May 1, 2025 | marketbeat.comAclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical OfficerMay 1, 2025 | msn.comAclaris Therapeutics appoints new Chief Medical OfficerApril 30, 2025 | uk.investing.comAclaris Therapeutics, Inc.: Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical OfficerApril 29, 2025 | finanznachrichten.deAclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical OfficerApril 29, 2025 | globenewswire.com2,266,667 Shares in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Bought by Decheng Capital LLCDecheng Capital LLC purchased a new position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 2,266,667 shares of the biotechnology company'sApril 28, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Buys Shares of 9,627,304 Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Adage Capital Partners GP L.L.C. bought a new stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 9,627,304 shares of the biotechnology company's stock, valued at approximaApril 28, 2025 | marketbeat.comRenaissance Technologies LLC Sells 520,181 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Renaissance Technologies LLC reduced its holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 38.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 850,519 shares of the biotechnology company's stock after selling 520,1April 28, 2025 | marketbeat.comMarshall Wace LLP Takes $6.53 Million Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Marshall Wace LLP acquired a new position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 2,634,065 shares of the biotechnologyApril 26, 2025 | marketbeat.comStrong week for Aclaris Therapeutics (NASDAQ:ACRS) shareholders doesn't alleviate pain of three-year lossApril 25, 2025 | uk.finance.yahoo.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of "Buy" from AnalystsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has been given an average rating of "Buy" by the eight analysts that are presently covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommApril 25, 2025 | marketbeat.comAclaris Therapeutics’ IND for ATI-052 candidate granted FDA clearanceApril 23, 2025 | markets.businessinsider.comAclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational AntibodyApril 23, 2025 | seekingalpha.comRock Springs Capital Management LP Has $15.39 Million Stock Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Rock Springs Capital Management LP increased its position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 125.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,204,309 shares of the bApril 23, 2025 | marketbeat.comVivo Capital LLC Invests $22.04 Million in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Vivo Capital LLC acquired a new position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 8,888,888 shares of the biotechnology company'sApril 23, 2025 | marketbeat.comWalleye Capital LLC Acquires Shares of 718,897 Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Walleye Capital LLC bought a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 718,897 shares of the biotechnology company's stock, valued at aApril 22, 2025 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Increase in Short InterestAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 6,030,000 shares, an increase of 26.7% from the February 28th total of 4,760,000 shares. Approximately 9.0% of the company's shares are short sold. Based on an average daily volume of 933,400 shares, the days-to-cover ratio is currently 6.5 days.April 1, 2025 | marketbeat.comCantor Fitzgerald Issues Negative Forecast for ACRS EarningsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Aclaris Therapeutics in a report issued on Tuesday, March 18th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the biotechnology company will post earnMarch 21, 2025 | marketbeat.comAclaris Therapeutics assumed with an Overweight at Cantor FitzgeraldMarch 19, 2025 | markets.businessinsider.comAclaris Therapeutics (NASDAQ:ACRS) Now Covered by Cantor FitzgeraldCantor Fitzgerald began coverage on shares of Aclaris Therapeutics in a research note on Tuesday. They set an "overweight" rating on the stock.March 19, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Grows Stock Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Connor Clark & Lunn Investment Management Ltd. lifted its stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 173.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 908,819 shares of the biotechnology company's stock afterMarch 19, 2025 | marketbeat.comAclaris Therapeutics (NASDAQ:ACRS) Stock Crosses Below 50-Day Moving Average - Should You Sell?Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Crosses Below 50 Day Moving Average - Here's WhyMarch 18, 2025 | marketbeat.comAclaris Therapeutics (NASDAQ:ACRS) Coverage Initiated by Analysts at ScotiabankScotiabank assumed coverage on shares of Aclaris Therapeutics in a report on Friday. They issued a "sector outperform" rating and a $15.00 price target on the stock.March 8, 2025 | marketbeat.comScotiabank Initiates Coverage of Aclaris Therapeutics (ACRS) with Sector Outperform RecommendationMarch 8, 2025 | msn.comAclaris Therapeutics initiated with an Outperform at ScotiabankMarch 8, 2025 | markets.businessinsider.com Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRS Media Mentions By Week ACRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACRS News Sentiment▼1.330.89▲Average Medical News Sentiment ACRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACRS Articles This Week▼33▲ACRS Articles Average Week Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Sana Biotechnology News Today Trevi Therapeutics News Today Bicara Therapeutics News Today Autolus Therapeutics News Today Evolus News Today Phathom Pharmaceuticals News Today ChromaDex News Today Stoke Therapeutics News Today Upstream Bio News Today Taysha Gene Therapies News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACRS) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
